

Spotlight Gastrointestinal System

Gastrointestinal System – Centre of Body & Health

In this Spotlight we focus on solutions for the gastrointestinal system. With our product portfolio and individual, application-related technical advice, we support you to develop contemporary dosage forms.


Being the centre of our body, the gastrointestinal system is a highly organised and sensitive network of different organs. While nutrition and digestion directly determine our well-being, they are not the only factors which cause stomach and intestinal problems and thus have impacts on our immune system. Complaints can vary from stomach pains to foam building, heartburn, dyspepsia and constipation.

With the active pharmaceutical ingredients (APIs) from our suppliers DuPont, Avesta and Omya we offer highly effective solutions for treating these symptoms.

The DuPont logo, featuring the word "DUPONT" in red capital letters with a small trademark symbol, flanked by two red curved lines.

Simethicone Compounds
& Emulsions


Contact us!



Macrogol (PEG)



Liveo™ Simethicone Compounds and Simethicone Emulsions




Silicones have a history of more than 50 years of safety and efficiency in healthcare-related applications and polydimethylsiloxanes are globally recognized both for their proven biocompatibility and for being one of the most tested materials for their safety. Silicones are used in many different registered pharmaceutical products. Silicones are well known for their use as antifoams to control or eliminate foam, and the use of simethicone in gastroenterology is well established. Simethicone Compounds, a blend of polydimethylsiloxane and silicone dioxide, have been specifically designed for use in medical and pharmaceutical applications requiring foam suppression or inhibition. Simethicone Emulsions are normally highly effective and versatile silicone defoamers

which can be used as supplied or further diluted with water. Both are used as excipients, active pharmaceutical ingredients and process aids in pharmaceutical applications. To assure consistent quality for use as pharmaceutical ingredients, Liveo™ brand antifoam products are manufactured, packaged, and tested at the Healthcare Industries Material Site utilizing US FDA GMP guidelines for Active Pharmaceutical Ingredients (APIs).


Product Profile: Simethicone and Emulsion

Product	Description	Typical Application	Regulatory Status
Q7-2243 LVA, Simethicone USP	Silicone antifoam Low volatile	Foam control in medical and pharmaceutical applications Prescription/ OTC/ medical device antifoamers	Simethicone EP Certificate of Suitability (CEP) Simethicone USP, US-DMF
Antifoam M Compound			Simethicone EP Certificate of Suitability (CEP)

Avesta Polyethylene Glycol (PEG)/ Macrogol



Polyethylene Glycol (PEG), as a pharmaceutical substance well known under the name **Macrogol**, is used as an osmotic-type laxative to treat constipation or to clear the colon before colonoscopy. Macrogol is the international non-proprietary name determined by the World Health Organization (WHO). Polyethylene glycols are polymers of ethylene oxide with the following chemical structure:



Within the pharmaceutical industry the number included in the names of polyethylene glycols indicates the average molecular weight. Macrogol 3350 / Macrogol 4000, widely used as active ingredients, have the ability to bind a defined amount of water, which is transmitted immediately into the large intestine. There it softens the faeces and increases its volume, which leads to a stimulation of intestinal peristalsis and increases the number of bowel movements.

Product Profile: Polyethylene Glycol / Macrogol

Product	Description	Typical Application	Regulatory Status
Macrogol 3350	Polyethylene Glycol (PEG)	Active for laxatives	Polyethylene Glycol, PEG USP/ USP-NF Macrogol EP/BP Certificate of Suitability (CEP) Good Manufacturing Practice (ICH Q7) Regulatory Dossier (EDMF)
Macrogol 4000			

Contact

Isabell Pallesche

Product Manager Pharma
Tel: +49 40 32008-620
i.pallesche@biesterfeld.com

Gitte Hobbeling

Product Manager Pharma
Tel: +49 40 32008-744
g.hobbeling@biesterfeld.com

Imprint

Published by:

Biesterfeld Spezialchemie GmbH – HealthCare
Ferdinandstrasse 41
20095 Hamburg

Phone: +49 40 32008-0
Fax: +49 40 32008-696
healthcare@biesterfeld.com
www.biesterfeld.com

Registered Office:

Hamburg, Commercial Register: AG Hamburg, HRB 66970, VAT-No. DE 196 930 661

Managing Director:

Peter Wilkes

Our raw material information, data and graphics were obtained from the records of our raw material suppliers.
Local availability of products might differ from country to country.

Disclaimer:

We shall not be liable for the suitability of the goods for the purpose intended by Customer, unless the achievement of a certain outcome of the utilization was expressly incorporated into the contract. Our advice, information or recommendations regarding application shall be provided to the best of our knowledge. As the actual application is beyond our scope of influence, and as the circumstances of such application are not completely foreseeable, written and verbal indications, suggestions etc. can only be provided on a non-binding basis. They shall in particular not release Customer from the obligation to examine our products and goods for their suitability with regard to the intended processes and purposes.

**Biesterfeld Spezialchemie GmbH**

Ferdinandstrasse 41
20095 Hamburg
Tel.: +49 40 32008-0
Fax: +49 40 32008-696
www.biesterfeld.com
healthcare@biesterfeld.com

Publisher:

Biesterfeld Spezialchemie GmbH – HealthCare, Ferdinandstraße 41,
20095 Hamburg, Germany, Tel.: +49 40 32008-0, www.biesterfeld.com

Disclaimer:

We shall not be liable for the suitability of the goods for the purpose intended by Customer, unless the achievement of a certain outcome of the utilisation was expressly incorporated into the contract. Our advice, information or recommendations regarding application shall be provided to the best of our knowledge. As the actual application is beyond our scope of influence, and as the circumstances of such application are not completely foreseeable, written and verbal indications, suggestions etc. can only be provided on a non-binding basis. They shall in particular not release Customer from the obligation to examine our products and goods for their suitability with regard to the intended processes and purposes.



September 2023